The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Novo Nordisk’s Wegovy faces sharp decline in growth forecasts and share value as competition intensifies and compounded drug ...

相反，一连串疲软的财报、减肥药遭遇的挫折以及高额关税的威胁，让礼来的投资者经历了一场过山车式的波动，最终却几乎回到了起点。目前，礼来股价较 8 月的历史高点下跌 21%，报每股 762 美元，市值为 7220 亿美元 —— 这一成绩不算差，但远未达到投资者预期的高位。

Kennedy has said that people who died from covid actually fell victim to chronic diseases such as obesity, diabetes, or asthma.